Barinthus Biotherapeutics (BRNS) Shares Outstanding (Weighted Average) (2020 - 2026)

Barinthus Biotherapeutics has reported Shares Outstanding (Weighted Average) for 7 years, with the latest figure at $40.8 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 1.45% year-over-year to $40.8 million; the trailing twelve-month figure through Mar 2026 stood at $40.8 million (up 1.45% YoY), and the FY2025 full-year result was $40.5 million, up 3.0% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $40.8 million, up from $40.5 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $40.8 million in Q1 2026, with the low at $37.2 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $38.9 million across 5 years, with a median of $38.8 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) soared 361.59% — and 2024, when it grew 1.3%.
• Barinthus Biotherapeutics' Shares Outstanding (Weighted Average) stood at $37.2 million in 2022, then rose by 3.06% to $38.4 million in 2023, then advanced by 2.51% to $39.3 million in 2024, then climbed by 3.0% to $40.5 million in 2025, then advanced by 0.79% to $40.8 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $40.8 million (Q1 2026), $40.5 million (Q4 2025), and $40.7 million (Q3 2025), per Business Quant data.